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effective way of multilineage chimerism
induction in the experimental and clinical
models. In this study, we introduce
combined vascularized skin/vascularized
bone transplantation model (VSNB) to
evaluate the effect of the VB trans-
plantation on tolerance induction across
strong MHC barrier, under a~-TCRmAb
+CsA treatment protocol.
Methods: Thirty-six-transplantations
between ACI (RT1 a) donors to Lewis
(RT11) recipients were performed in three
experimental groups of six animals each.
In isograft control group and allograft
rejection control group no treatment was
applied. The experimental group III of
vascularized skin /vascularized bone
allograft TCRlCsA for 7 days only. The
efficacy of (VS/BM) was treated with ab
immunosuppressive treatment and the
level of chimerism in the peripheral blood
of recipients were determined by flow
cytometry (FC). Standard H+E technique
was applied for the evaluation of the grade
of graft rejection.
Results: The Isograft Control Group I
transplants survived indefinitely. In allo-
graft rejection control transplants were
rejected between 5 and 9 days post-trans-
plant. The survival time was significantly
(p<0.05) extended in the VS/BM group up
to 90-125 days after treatment cessation.
MLR revealed no response to the host and
donor antigens but strong reactivity to the
third party (BN) alloantigens. Two-color FC
analysis of the RT1 a antigen expression in
the peripheral blood of the VSBM
recipients confirmed the presence of the
donor specific chimerism ranged form 12%
to 25% at day 63 post-transplant. At day
63 post-transplant the skin biopsies from
VS/BM recipients revealed no signs of
rejection.
Conclusion: Transplantation of the
vascularized skin with vascularized bone
resulted in significant prolongation of the
allograft survival. Allotransplantation of the
vascularized bone with marrow natural
micro-anatomic environment increases of
the donor-derived stem and progenitor
cells engraftment resulted in the
establishment of the stable, donor specific
chimerism.
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Purpose: Recently, we induced donor
specific tolerance to rat hind-limb allografts
under 35 days course of ab TCR mAb and
Cyc\osporine A. In this report, we inve-
stigated the role of shorter ab-TCR/CsA
protocols on the tolerance induction.
Materials and Methods: We performed
fifty-two hind-limb transplantations,
between Lewis-Brown-Norway (LBN, F1 )
donors and Lewis recipients to test the
impact of 21, 7 and 5 day protocols of
combined ab-TCR/CsA treatment on
tolerance induction. Donor specific
tolerance and immunocompetence were
tested by mixed lymphocyte reaction
(MLR) in vitro and by standard skin
grafting in vivo. The efficacy of immuno-
suppressive protocol and donor specific
chimerism was assessed by flow cyto-
metry.
Results: All transplants under 5, 7, and
21 days of combined ab-TCR/CsA therapy
survived over 350 days. Clinical tolerance
and immunocompetence were confirmed
by skin grafting in vivo and MLR in vitro.
Flow cytometry revealed· high levelot do-
nor chimerism in the peripheral blood of
the long term survivors.
Conclusion: The extention of survival
of limb allografts and allounresponsive-
ness were directly associated with the de-
velopment of stable chimerism in the tole-
rated recipients.
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